Pharmaceutical intermediates
Lapatinib Intermediates
2 pharmaceutical intermediates for Lapatinib. Indication: Breast Neoplasms.
About Lapatinib
- Originator
- Novartis Pharmaceuticals Corp
- Indication
- Breast Neoplasms
- Approved Date
- 03/13/2007
Available intermediates
2 intermediates currently listed for Lapatinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-Chloro-4-(3-fluorobenzyloxy)aniline | 202197-26-0 | / | / |
| 5-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]quinazolin -6- yl]furan-2-carboxaldehyde | 231278-84-5 | / | / |
Building toward Lapatinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →